Hot line:010-61006450
ENAbout Us
Stock(600222)
Leadingpharm was founded in 2005.In 2015, Leadingpharm was reorganized and listed with Henan Tailong Pharmaceutical (Stock Code: 600222), aiming to promote the development of China's pharmaceutical industry with innovative modes of research, development and service, as well as information technology. Based on the international perspective, Leadingpharm has formed its core competitive advantages, which are internationalization, integration and industrialization. With the mature and perfect drug R & D management system, rich project experience and the team of thousands of senior experts at home and abroad, Leadingpharm has formed a CXO Service System covering the whole industry chain including preclinical research, clinical CRO, CDMO and MAH, and realized the full coverage of innovative drugs, high-end complex preparations, cell gene therapy drugs and other fields, which can provide real one-stop service for global customers.
Services
-
API and Excipients R&D
Synthesis and Development of Raw and Auxiliary Materials， Research on the Substitution of High-end Auxiliary Materials
-
Preparation R&D
Formulation and Process Development of Generic Drugs, Improved New Drugs and Innovative Drugs
-
Analytical Test
Elemental Analysis, Impurity Detection, Analysis of Complex Preparation Excipients, Compatibility Detection
-
IVIVR
IVIVR Model Establishment, BE Guidance, Risk Assessment
-
Clinical CRO
Phase I-IV clinical trial, PK/PD, IIT, medical service, third-party audit
-
CDMO
Large Molecule Drugs CDMO,Small Molecule Drugs CDMO
-
MAH Services
Project Establishment Service, Pharmaceutical Administration Service, Quality Management System Service
-
Other services
Park Services, Financial Services
- Shenyang
- Dalian
- Hangzhou
- Beijing
- Shijiazhuang
- Zhengzhou
- Wuhan
- Changsha
- Guangzhou
- Taiyuan
- Guizhou
- Xian
- Tianjin
-
Zhengzhou
Zhengzhou CDMO Base
Zhengzhou Pharmaceutical Research Institute
· 4000m2 R & D Laboratory
· Liquid Preparation R & D + Solid Preparation R & D
Large & Small Molecule CDMO Platform -
Beijing
Beijing Clinical Management Center
·Phase I ~ IV Clinical Study of Innovative Drugs, BE Study, etc.
Beijing Research Institude
· 10000m2 R & D Laboratory
· API Synthesis, Preparation R & D, Analysis and Detection, Project Approval, Registration, IVIVR
Miyun High-end API R & D Base
·2000m2 R & D laboratory
·Research on Imitation and Substitution of High-end Auxiliary Materials -
Chongqing
Chongqing High-end Preparation R & D and MAH Base and CDMO
Chongqing Research Institute
·4000m2 R & D Laboratory
·R & D of High-end Solid Preparations and Innovative Drugs
-
Hangzhou
Hangzhou High-end Pediatric Preparation R & D Base
(the first high-end preparation research institute for children's medicine in China)·3000m2 R & D Laboratory
·R & D of High-end Pediatric Preparations
News
- Company News
-
Strategic Cooperation | The Intelligent Development Joint Research Center for Improved New Drugs Built by Leadingpharm and Peking University Third Hospital has been Officially Launched
2022-11-12 -
Leadingpharm (Chongqing) Medical Technology Has Been Grandly Opened, Which Will Further Improve the Strategic Layout of CXO in the Whole Country!
2022-11-01 -
Alumni Exchange | CEIBS EMBA 2021 Class 4 Visited Leadingpharm
2022-08-24
010-61006450
Address：
Marketing Department：
Leadingpharm
Pharm News
010-61006450
